Merck And Teva Settle Temodar Patent Suit, But Appeals Case Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva will launch its generic only if an appeals court finds the Temodar patent is unenforceable; otherwise it can do so six months before the patent expires.
You may also be interested in...
Business News, In Brief
Pfizer Lays Out Primary Care Business Development Opportunities
Business News, In Brief
Pfizer Lays Out Primary Care Business Development Opportunities
Famvir Patent Settlement: 17 Months After At-Risk Launch, Teva Must Pay Novartis
Teva's at-risk strategy produces another muddled outcome as the generic firm now owes Novartis royalties on U.S. sales of its generic version of the herpes drug.